sofwave collagen loss face glp-1 weight loss The Effect of Sofwave Treatment in NYC &

In Phase 2 obesity trials, retatrutide produced approximately 24% mean body-weight reduction at 48 weeks at the 12 mg dose the largest weight-loss effect reported for any GLP-1-class compound to date

JAMA Health Forum

Phase 3 results are expected throughout the remainder of the TRIUMPH program, with potential FDA approval estimated for 2027 at the earliest

Once someone has done all the right things for nutrition, fitness, sleep, stress management, and frailty prevention, then having a conversation about adding a pharmacologic option for longevity or optimization becomes appropriate. The Takeaway GLP-1 medications, like semaglutide and tirzepatide, were originally developed for diabetes, but researchers are now exploring if they may extend lifespan and help people maintain good health for a longer period of time

The pattern persists across patient subgroups, including those with diabetes, cardiovascular disease, and obesity diagnoses

However, due to cost concerns, some healthcare providers are prescribing GLP-1 alternatives, such as SGLT2s (sodium-glucose cotransporter 2 inhibitors), for addressing cardiovascular risk